Biomarkers in the prediction of contrast media induced nephropathy - the BITCOIN study.
Acute Kidney Injury
/ chemically induced
Aged
Area Under Curve
Biomarkers
/ blood
Contrast Media
/ adverse effects
Coronary Angiography
/ adverse effects
Creatinine
/ blood
Female
Glomerular Filtration Rate
Hepatitis A Virus Cellular Receptor 1
/ analysis
Humans
Leukocyte L1 Antigen Complex
/ urine
Lipocalin-2
/ urine
Male
Middle Aged
Prognosis
Prospective Studies
Proteinuria
ROC Curve
Renal Insufficiency, Chronic
/ complications
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
01
2020
accepted:
04
06
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
25
9
2020
Statut:
epublish
Résumé
Subjects with chronic kidney disease are at increased risk for contrast-induced acute kidney injury (CI-AKI). Risk stratification is traditionally based on glomerular filtration rate (GFR) and proteinuria. The present trial examines, whether tubular and inflammatory biomarkers are able to identify subjects at increased risk as well. We performed a prospective study in 490 patients undergoing coronary angiography. An increase of serum creatinine concentration ≥ 0.3 mg/dl from baseline to day 2-3 was defined as primary endpoint (CI-AKI). Urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and calprotectin were assessed < 24h before coronary angiography. Prognostic accuracy was assessed by receiver operating characteristics (ROC) calculations. 30 (6.1%) patients suffered from CI-AKI (27 AKIN stage I, 3 AKIN stage II, 0 AKIN stage III). Those subjects who developed CI-AKI had 3.1 fold higher baseline urinary NGAL/creatinine ratios than those without CI-AKI (60.8 [IQR 18.7-93.1] μg/mg vs. 19.9 [IQR 12.3-38.9] μg/mg, p = 0.001). In those subjects without clinically overt CKD (eGFR > 60 ml/min, urinary albumin creatinine ratio <30 mg/g), the NGAL/creatinine ratio was 2.6 higher in CI-AKI vs. no CI-AKI (47.8 [IQR 11.8-75.3] vs. 18.6 [IQR 11.7-36.3] μg/mg). No significant differences were obtained for KIM-1 and calprotectin (p>0.05 each). ROC analyses revealed an area under the curve (AUC) of 0.68 (95% CI 0.60-0.81) for NGAL/creatinine. An NGAL/creatinine ratio < 56.4 μg/mg has a negative predictive value of 96.5%. The present study is the largest investigation on the use of urinary biomarkers for CI-AKI risk stratification so far. It shows that NGAL provides prognostic information beyond the glomerular biomarkers eGFR and proteinuria.
Sections du résumé
BACKGROUND
Subjects with chronic kidney disease are at increased risk for contrast-induced acute kidney injury (CI-AKI). Risk stratification is traditionally based on glomerular filtration rate (GFR) and proteinuria. The present trial examines, whether tubular and inflammatory biomarkers are able to identify subjects at increased risk as well.
METHODS
We performed a prospective study in 490 patients undergoing coronary angiography. An increase of serum creatinine concentration ≥ 0.3 mg/dl from baseline to day 2-3 was defined as primary endpoint (CI-AKI). Urinary neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and calprotectin were assessed < 24h before coronary angiography. Prognostic accuracy was assessed by receiver operating characteristics (ROC) calculations.
RESULTS
30 (6.1%) patients suffered from CI-AKI (27 AKIN stage I, 3 AKIN stage II, 0 AKIN stage III). Those subjects who developed CI-AKI had 3.1 fold higher baseline urinary NGAL/creatinine ratios than those without CI-AKI (60.8 [IQR 18.7-93.1] μg/mg vs. 19.9 [IQR 12.3-38.9] μg/mg, p = 0.001). In those subjects without clinically overt CKD (eGFR > 60 ml/min, urinary albumin creatinine ratio <30 mg/g), the NGAL/creatinine ratio was 2.6 higher in CI-AKI vs. no CI-AKI (47.8 [IQR 11.8-75.3] vs. 18.6 [IQR 11.7-36.3] μg/mg). No significant differences were obtained for KIM-1 and calprotectin (p>0.05 each). ROC analyses revealed an area under the curve (AUC) of 0.68 (95% CI 0.60-0.81) for NGAL/creatinine. An NGAL/creatinine ratio < 56.4 μg/mg has a negative predictive value of 96.5%.
CONCLUSIONS
The present study is the largest investigation on the use of urinary biomarkers for CI-AKI risk stratification so far. It shows that NGAL provides prognostic information beyond the glomerular biomarkers eGFR and proteinuria.
Identifiants
pubmed: 32673348
doi: 10.1371/journal.pone.0234921
pii: PONE-D-20-01191
pmc: PMC7365403
doi:
Substances chimiques
Biomarkers
0
Contrast Media
0
HAVCR1 protein, human
0
Hepatitis A Virus Cellular Receptor 1
0
Leukocyte L1 Antigen Complex
0
Lipocalin-2
0
Creatinine
AYI8EX34EU
Banques de données
figshare
['10.6084/m9.figshare.12369521']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0234921Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Scand J Clin Lab Invest. 2014 Mar;74(2):81-8
pubmed: 24304491
Clin J Am Soc Nephrol. 2011 Oct;6(10):2347-55
pubmed: 21885792
Am J Cardiol. 2015 Jun 15;115(12):1636-42
pubmed: 25891989
Pediatr Nephrol. 2016 Dec;31(12):2353-2363
pubmed: 27286687
Transplantation. 2017 Feb;101(2):387-394
pubmed: 26901081
Nephrol Dial Transplant. 2016 Sep;31(9):1460-70
pubmed: 27270293
Crit Care. 2007;11(2):R31
pubmed: 17331245
J Am Soc Nephrol. 2005 Nov;16(11):3365-70
pubmed: 16177006
Kidney Blood Press Res. 2018;43(4):1255-1262
pubmed: 30078006
Kidney Blood Press Res. 2018;43(5):1563-1572
pubmed: 30347407
Cardiorenal Med. 2020;10(3):162-174
pubmed: 32289786
Acta Med Acad. 2017 May;46(1):34-43
pubmed: 28605926
Cell Physiol Biochem. 2017;43(1):209-222
pubmed: 28854431
Clin Nephrol. 2013 Feb;79(2):85-92
pubmed: 23110770
Lancet. 2017 Apr 1;389(10076):1312-1322
pubmed: 28233565
Am J Cardiol. 2009 Jun 15;103(12):1657-62
pubmed: 19539072
Toxicology. 2005 Apr 15;209(2):185-7
pubmed: 15767033
Can J Cardiol. 2017 Jun;33(6):724-736
pubmed: 28545621
Scand J Clin Lab Invest. 2010 Sep;70(5):374-82
pubmed: 20509756
N Engl J Med. 2018 Feb 15;378(7):603-614
pubmed: 29130810
J Clin Med. 2019 Jan 10;8(1):
pubmed: 30634660
Acta Physiol (Oxf). 2013 Apr;207(4):700-8
pubmed: 23336369
Inflamm Allergy Drug Targets. 2011 Aug;10(4):260-71
pubmed: 21539514
PLoS One. 2014 Nov 17;9(11):e113006
pubmed: 25402277
Eur J Pediatr. 2017 Jun;176(6):745-755
pubmed: 28409285
Saudi J Kidney Dis Transpl. 2009 Mar;20(2):240-5
pubmed: 19237811
Insights Imaging. 2013 Dec;4(6):811-20
pubmed: 24092564
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Am Soc Nephrol. 2016 Jul;27(7):2109-21
pubmed: 26538631
PLoS One. 2016 Jan 08;11(1):e0146395
pubmed: 26745147